Thelansis

Non-Small Cell Lung Cancer (NSCLC) Epidemiology Insights Thelansis’s “Non-Small Cell Lung Cancer (NSCLC) Epidemiology Insights and Forecast Report – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies. Key business questions answered: 20-year historical and forecast data (2020–2040) Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes) Granular patient population coverage by year and geography Detailed segmentation by age, gender, subpopulations, comorbidities, ...

Non-Small Cell Lung Cancer (NSCLC) Epidemiology Insights Thelansis’s  “Non-Small Cell Lung Cancer (NSCLC) Epidemiology Insights and Forecast Report – 2020 To 2040″  provides an analysis of disease burden, characterized by disease definition, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies . Non-Small Cell Lung Cancer (NSCLC) Overview Non‑small cell lung cancer (NSCLC) is the predominant form of lung cancer, accounting for approximately 85% of all cases. Around 15–20% are diagnosed at an early stage, where surgical resection, often combined with adjuvant chemotherapy or radiotherapy, offers the best c...